Virus-like particle display of HER2 induces potent anti-cancer responses

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• HER2 overexpression drives 20-30% of invasive breast cancers.
• Monoclonal antibody therapy for HER2-positive cancers is limited by cost, side effects, and resistance.
• Active vaccination offers a potentially safer, more effective, and cheaper alternative, but faces challenges in inducing durable autoantibody responses due to immune tolerance.

Purpose of the Study:

• To evaluate a novel virus-like particle (VLP) based vaccine platform for inducing therapeutically potent anti-HER2 autoantibody responses.
• To assess the efficacy of the HER2-VLP vaccine in preventing and treating HER2-positive mammary carcinomas in preclinical models.

Main Methods:

• Directional, high-density display of human HER2 on the surface of VLPs.
• Prophylactic vaccination of human HER2 transgenic mice to assess prevention of spontaneous mammary carcinomas.
• Tumor implantation studies in wild-type mice to evaluate the vaccine's efficacy in inhibiting HER2-positive tumor growth.

Main Results:

• The HER2-VLP vaccine successfully induced therapeutically potent anti-HER2 autoantibody responses.
• Prophylactic vaccination reduced spontaneous mammary carcinoma development by 50%-100% in HER2 transgenic mice.
• The vaccine inhibited the growth of HER2-positive tumors implanted in wild-type mice.

Conclusions:

• The HER2-VLP vaccine platform is effective in inducing potent anti-HER2 autoantibody responses.
• This vaccine demonstrates significant potential for the prevention and treatment of HER2-positive cancers.
• The VLP platform may be a valuable tool for developing vaccines against other non-communicable diseases.